GlobeNewswire

ContextVision announces first CE marked digital pathology product

Share

STOCKHOLM – June 29, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced that its first digital pathology product in a planned portfolio has been granted CE mark status. This means that INIFY® Prostate Screening is now available for routine clinical use within the European Union.

“I am proud of the great performance by our outstanding multidisciplinary team in reaching this company milestone. Healthcare systems around the world are already under great stress due to heavy workloads and lack of resources – and both patient numbers and cancer rates are only increasing. Intelligent technology will be a vital key to addressing these challenges, with powerful tools supporting the medical professionals in terms of efficiency and precision,” says Fredrik Palm, CEO at ContextVision.

“We are a first mover in what I am certain will become a billion-dollar market.”

ContextVision is an independent world-wide leader within digital image enhancement for multiple imaging modalities. With its 35-year history of developing advanced software for digital image analysis and enhancement, it was a natural step forward to invest in and aim for a leading position within clinical pathology – a discipline where today’s ongoing digitalization offers huge opportunities.

INIFY® Prostate Screening is a powerful AI-based software that predicts, outlines and quantifies suspected cancerous areas in a series of prostate biopsies. It pre-sorts slides in a worst-first order, allowing pathologists to get right to work on the most relevant areas. While the product can be used as a stand-alone unit, even more importantly it is designed to be seamlessly integrated into pathology laboratories’ existing LIS (Laboratory Information Systems) or PACS (Picture Archiving and Communication Systems).

“I can testify that it is really easy to use, saves time and helps highlight suspicious areas for cancer.”

The predicting engine in INIFY® Prostate Screening is built on deep learning algorithms, trained and adapted by ContextVision’s skilled research scientists, resulting in proprietary high-performance algorithms with pixel-level accuracy. Our unique, patented MasterAnnotation™ method has been used to create the training data on which the engine is built. Here, multiplex immunofluorescent staining is used to objectively identify and highlight cancer areas and other structures with extreme precision, which in turn are quality assured by certified pathologists.

“We have been involved in the development of INIFY® Prostate Screening and can assure it fits laboratory needs. A prototype version of the product has been used daily for two years in our fully digital pathology workflow here in Catania, and I can testify that it is really easy to use, saves time and helps highlight suspicious areas for cancer,” says Dr. Filippo Fraggetta, chief pathologist at the Pathology Unit of Cannizzaro Hospital.

ContextVision clearly sees the need for a product that can support the pathologist in identifying prostate cancer faster and more easily, with the highest possible precision. INIFY® Prostate Screening will facilitate the transformation of clinical pathology into a digital discipline, ultimately offering much higher quality and standardization.

“INIFY®Prostate Screening will allow pathologists to focus their time on assessing and examining prostate specimens containing suspicious cancer areas, while minimizing time spent on benign tissue. Knowing that collaboration with the medical profession is essential, we have worked closely with multiple pathology labs around the world, all at the forefront of digitalization. Now, with our first product available for clinical use within EU, we can expect several full installations in the clinical workflow this fall. We are a first mover in what I am certain will become a billion-dollar market,” says Palm. “Prostate cancer is the second most common cancer in the world among men, with 2.3 million biopsy procedures carried out annually in Europe and the US alone. With INIFY® Prostate Screening, we have laid a solid groundwork – which in turn can be further adapted to address other cancer types, such as colon and lung cancer.”


For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com.

###

About ContextVision

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.

###

This information is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on June 29, 2020.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 10:07:00 CESTPress release

Auction date2020-09-18Loan1061Coupon0.75 %ISIN-codeSE0011281922Maturity2029-11-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln3,450Volume bought, SEK mln1,000Number of bids8Number of accepted bids1Average yield-0.097 %Lowest accepted yield-0.097 %Highest yield-0.097 %% accepted at lowest yield 100.00 Auction date2020-09-18Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln4,950Volume bought, SEK mln1,000Number of bids14Number of accepted bids2Average yield0.005 %Lowest accepted yield0.004 %Highest yield0.006 %% accepted at lowest yield 100.00

Saniona deltar i den virtuella konferensen Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 202018.9.2020 08:00:00 CESTPressemelding

PRESSMEDDELANDE 18 september 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets koncernchef och VD Rami Levin kommer att delta i ett virtuellt ”samtal vid brasan” i samband med konferensen Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit som anordnas 21-23 september 2020. Närmare uppgifter om det virtuella samtalet vid brasan presenteras nedan. Oppenheimer & Co. 2020 Fall Healthcare Life Sciences & MedTech Summit Datum: Tisdag 22 september 2020 Tid: 10.50 ET Länk till webbsändning: https://wsw.com/webcast/oppenheimer5/sanion.st/3751533 Samtalet vid brasan kommer att websändas live, och kan nås via sidan ”Intervjuer och webbsändningar” på Sanionas webbplats: https://saniona.com/se/investors/interviews-webcasts/. Efter livesändningen kommer samtalet att finnas arkiverat på Sanionas webbplats i ungefär 90 dagar. För mer information, var vänlig kontakta Trista Morrison, Chief Communi

Saniona to Participate in Oppenheimer’s Virtual 2020 Fall Healthcare Life Sciences & MedTech Summit18.9.2020 08:00:00 CESTPress release

PRESS RELEASE September 18, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will participate in a virtual fire side chat at the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit being held September 21–23, 2020. Details on the virtual fire side chat are shown below. Oppenheimer & Co. 2020 Fall Healthcare Life Sciences & MedTech Summit Date: Tuesday September 22, 2020 Time: 10:50 a.m. ET Webcast Link: https://wsw.com/webcast/oppenheimer5/sanion.st/3751533 A live webcast of the fire side chat will be available in the Interviews & Webcasts section of the Saniona website found here: https://saniona.com/investors/interviews-webcasts/. After the live webcast, this event will remain archived on the Saniona website for approximately 90 days. For more information, please contact Trista Morrison, Chief Communications Officer. Mobile + 1 (781) 810 9227

Scandinavian Tobacco Group A/S issues EUR 300 million Corporate Bond18.9.2020 08:00:00 CESTPress release

Company Announcement No. 27/2020 Copenhagen, 18 September 2020 Scandinavian Tobacco Group A/S issues EUR 300 million Corporate Bond The information contained herein is not a release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia or any other jurisdiction in which such release, publication or distribution would be unlawful.This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities in Scandinavian Tobacco Group A/S or STG Global Finance B.V. in the United States, Canada, Japan or Australia or any other jurisdiction. STG Global Finance B.V., a wholly-owned subsidiary of Scandinavian Tobacco Group A/S, has successfully priced an issuance of a 5 year unsecured corporate bond for a principal amount of EUR 300 million with maturity in September 2025 and with a coupon of 1.375%. The issuance was more than two times oversubscribed. The bonds are guaranteed by Scandinavian Tobacco Group

Scandinavian Tobacco Group A/S udsteder EUR 300 millioner erhvervsobligationer18.9.2020 08:00:00 CESTpressemeddelelse

Selskabsmeddelelse Nr. 27/2020 København, 18. september 2020 Scandinavian Tobacco Group A/S udsteder EUR 300 millioner erhvervsobligationer Denne meddelelse og indholdet heraf må ikke udleveres, offentliggøres eller distribueres, direkte eller indirekte, i USA, Canada, Japan eller Australien eller i nogen anden jurisdiktion, hvor udlevering, offentliggørelse eller distribution ville være ulovlig.Denne meddelelse udgør ikke et tilbud om at sælge eller en opfordring til at fremsætte tilbud om at købe nogen værdipapirer i Scandinavian Tobacco Group A/S eller STG Global Finance B.V. i USA, Canada, Japan eller Australien eller nogen anden jurisdiktion. STG Global Finance B.V., et helejet datterselskab til Scandinavian Tobacco Group A/S, har gennemført prisning af en udstedelse af en 5-års usikret erhvervsobligation garanteret af Scandinavian Tobacco Group A/S med en hovedstol på EUR 300 millioner, forfald i september 2025 og en kuponrente på 1,375 %. Udstedelsen blev overtegnet lidt over to

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines18.9.2020 07:03:00 CESTPress release

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.1Using the Elecsys Anti-SARS-COV-2 S antibody test, together with the Elecsys Anti-SARS-CoV-2* test launched in May, can help to more effectively determine the percentage of a population who already have antibodies against SARS-COV-2. Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can p